Thanks to a steady stream of subsequent announcements and tie-up partners and a 25% gain today, the stock of AnGes Inc. now commands the highest weighting of almost 10% on the $55 billion Tokyo Stock Exchange Mothers startup board TOKYO : A Japanese biopharma venture has surged almost 400% in just over two months on hopes that its vaccine candidate for the coronavirus will be successful.
AnGes Inc., a spin-off from Osaka University, announced March 5 that it was developing a DNA vaccine for coronavirus. Thanks to a steady stream of subsequent announcements and tie-up partners and a 25% gain on Thursday, the stock now commands the highest weighting of almost 10% on the 5.88 trillion yen ($55 billion) Tokyo Stock Exchange Mothers startup